BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) reported Q3 EPS of $0.04, $0.14 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $113.4 million versus the consensus estimate of $113.2 million.

Earnings